MyFinsight
Home
Blog
About
Contact
Download
Download image
Issuance of common shares
pursuant to exercise of...
$11,531K
Issuance of common shares
pursuant to espp
$88K
Disposition of investments
in marketable...
$16,000K
Net cash provided by
financing activities
$11,619K
Net cash provided by
investing activities
$2,199K
Canceled cashflow
$13,800K
Increase in cash and cash
equivalents
$5,698K
Canceled cashflow
$8,120K
Net income (loss)
$169,695K
Stock-based compensation
expense
$1,359K
Accounts receivable
-$1,160K
Change in fair value of
contingent consideration
$209K
Non-cash interest
expense
$17K
Purchase of investments
in marketable...
$13,800K
Net cash used in
operating activities
-$8,110K
Effect of foreign
exchange rate changes on...
-$10K
Canceled cashflow
$172,440K
Increase (decrease) in
accounts and other...
$178,741K
Accounts payable and
accrued liabilities
-$985K
Net accretion and
amortization of investments...
$354K
Depreciation
-$341K
Prepaid expenses and
other assets
$195K
Back
Back
Cash Flow
Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp (ABUS)
source: myfinsight.com